Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Jubilant Life Sciences Ltd (JUBILANT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9847
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company’s product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical ingredients (APIs), solid dosage formulations, life science chemicals, nutritional products, fine ingredients, advance intermediates and crop science ingredients. It also provides contract manufacturing of sterile injectables and drug discovery and development services. The company caters its products and services to customers across India, North America, Canada, Europe and China. It owns and operates cGMP compliant manufacturing facilities, and research and development centers in India, the US and Canada. Jubilant is headquartered in Noida, Uttar Pradesh, India.

Jubilant Life Sciences Ltd (JUBILANT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Jubilant Pharma Plans to Acquire Pharma Business in US 14
Partnerships 15
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16
Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19
Licensing Agreements 20
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21
Equity Offering 22
Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22
Debt Offering 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24
Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25
Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26
Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27
Jubilant Life Sciences Plans Debt Offering For US$250 Million 28
Asset Transactions 29
Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29
Acquisition 30
Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30
General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32
Jubilant Life Sciences Ltd – Key Competitors 33
Jubilant Life Sciences Ltd – Key Employees 34
Jubilant Life Sciences Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 38
Financial Announcements 38
Oct 22, 2018: Jubilant Life Sciences: Q2 & H1 ‘FY19 Results 38
Jul 27, 2018: Jubilant Life Sciences- Q1 FY 2019 Results – Jubilant Reports Strong Performance in Q1’FY19 Revenue at Rs. 2,079 Crore, up 34% YoY 42
May 09, 2018: Jubilant Life Sciences – Q4/ FY2018 Results- Jubilant Reports Strong Performance in Q4’FY18 Revenue at Rs. 2,252 crore, up 41% YOY; EBITDA at Rs. 481 crore, up 52% YOY PAT at Rs 155 crore 45
Jan 17, 2018: Jubilant Reports Record Performance In Q3 FY2018; Highest Ever Revenues And Profits Revenue At Rs. 2,068 Crore, Up 42% YOY and Ebitda at Rs. 431 Crore, Up 28% YOY Pat At Rs. 213 Crore, Up 78% YOY With 49
Oct 28, 2017: Jubilant Life Sciences: Q2/H1 FY2018 Results 53
Jul 18, 2017: Jubilant Life Sciences: Q1 FY2018 Result 57
Jul 18, 2017: Jubilant Reports Q1 FY2018 Revenue of Rs. 1,596 Crore, UP 10% YOY Pharma Segment Records Highest Ever Sales Ebitda of Rs. 344 Crore and Margins of 21.6%; Pat of Rs. 147 Crore 59
May 23, 2017: Jubilant Life Sciences Reports Total RevenueOf INR26.2 Billion In Fiscal 2017 61
Feb 07, 2017: Jubilant Reports Strong Performance In Q3 FY17; Sales At Rs. 1,492 Crore, Up By 7% YOY EBITDA At Rs. 337 Crore; Up 9% YOY With Margins Of 22.6%; PAT At Rs. 120 Crore 62
Corporate Communications 65
Oct 22, 2018: Jubilant Life Sciences announces appointment of directors 65
Jan 17, 2018: Jubilant Life Sciences: Changes in the Board of Directors 66
Legal and Regulatory 67
Mar 04, 2018: Jubilant Life Sciences: Commissioner of State Excise Cancelled License DS-1 License and Form-I License relating to the Distillery operations 67
Jan 25, 2017: Jubilant Life Sciences is now Responsible Care 14001: 2013 certified 68
Other Significant Developments 69
Jun 01, 2017: Jubilant Life Sciences Provides Update on Gajraula Manufacturing Unit 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Jubilant Pharma Plans to Acquire Pharma Business in US 14
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16
Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21
Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22
Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24
Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25
Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26
Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27
Jubilant Life Sciences Plans Debt Offering For US$250 Million 28
Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29
Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30
General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32
Jubilant Life Sciences Ltd, Key Competitors 33
Jubilant Life Sciences Ltd, Key Employees 34
Jubilant Life Sciences Ltd, Other Locations 35
Jubilant Life Sciences Ltd, Subsidiaries 35

List of Figures
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Qualcomm Incorporated (QCOM):医療機器:M&Aディール及び事業提携情報
    Summary Qualcomm Incorporated (Qualcomm) is a technology and communication company. The company designs and manufactures digital wireless telecommunications products and services. Qualcomm offers integrated circuits and system software for wireless mobile devices. The major technologies such as code …
  • Burgan Bank Sak:企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Women’s Choice Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Women's Choice Pharmaceuticals LLC (WCP) is a pharmaceutical company that offers prescription products for women’s health care and urology markets. The company’s products include fem pH, a therapeutic vaginal jelly that is used to promote and maintain vaginal acidity caused by diabetes, horm …
  • CSL Ltd (CSL):製薬・医療:M&Aディール及び事業提携情報
    Summary CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and second …
  • L’Oreal USA, Inc.:企業の戦略的SWOT分析
    L'Oreal USA, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Ilyushin Aviation Complex OJSC:企業の戦略・SWOT・財務情報
    Ilyushin Aviation Complex OJSC - Strategy, SWOT and Corporate Finance Report Summary Ilyushin Aviation Complex OJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • PTC, Inc. (PTC):企業の財務・戦略的SWOT分析
    PTC, Inc. (PTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Ghent University-製薬・医療分野:企業M&A・提携分析
    Summary Ghent University (Ghent) is an educational institution that provides research-based educational programmes and services. The university provides educational services such as international courses, preparatory language courses, programmes for exchange students and language courses, among othe …
  • AstraZeneca PLC:企業のM&A・事業提携・投資動向
    AstraZeneca PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AstraZeneca PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Expedia Inc:戦略・SWOT・企業財務分析
    Expedia Inc - Strategy, SWOT and Corporate Finance Report Summary Expedia Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Salzgitter Klockner-Werke GmbH:企業の戦略・SWOT・財務情報
    Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report Summary Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • De’Longhi S.p.A. (DLG):企業の財務・戦略的SWOT分析
    De'Longhi S.p.A. (DLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Diagnostics For All Inc:企業の製品パイプライン分析2018
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • Nippon Shinyaku Co Ltd (4516):製薬・医療:M&Aディール及び事業提携情報
    Summary Nippon Shinyaku Co Ltd (Nippon) is a pharmaceutical company that develops, manufactures and sells ethical pharmaceuticals and functional foods. The company offers a wide range of products including drugs for pain, inflammation, and allergies; urological diseases; hematologic malignancies; ga …
  • Katrina Group Ltd. (1A0):企業の財務・戦略的SWOT分析
    Katrina Group Ltd. (1A0) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務分析
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Smartac Group China Holdings Ltd (395):企業の財務・戦略的SWOT分析
    Smartac Group China Holdings Ltd (395) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Evgen Pharma Plc (EVG):企業の財務・戦略的SWOT分析
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company focused on the development of sulforaphane-based compounds for the treatment of cancer and neurological disease. Its pipeline product SFX-01 targets STAT3 signalling to inhibit stem-like c …
  • Banco BPM S.p.A.:企業の戦略・SWOT・財務分析
    Banco BPM S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Banco BPM S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Applus Services, S.A.:企業のM&A・事業提携・投資動向
    Applus Services, S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Applus Services, S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆